JPMorgan Chase & Co. Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,200.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by JPMorgan Chase & Co. from $1,150.00 to $1,200.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, April 30th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an overweight rating in a report on Friday. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a report on Tuesday, July 23rd. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a report on Thursday, July 11th. Finally, Argus raised their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research report on Tuesday, June 25th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Trading Down 1.0 %

REGN opened at $1,071.28 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.96 and a quick ratio of 4.51. Regeneron Pharmaceuticals has a fifty-two week low of $765.28 and a fifty-two week high of $1,115.00. The firm has a market capitalization of $118.04 billion, a PE ratio of 31.65, a P/E/G ratio of 2.34 and a beta of 0.13. The company’s 50-day moving average is $1,043.43 and its 200 day moving average is $983.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business posted $8.79 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 31.0% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 427 shares of the biopharmaceutical company’s stock valued at $449,000 after buying an additional 101 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 103.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 2,533 shares of the biopharmaceutical company’s stock valued at $2,662,000 after buying an additional 1,290 shares in the last quarter. Savant Capital LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 13.7% during the 2nd quarter. Savant Capital LLC now owns 624 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 75 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.5% during the 2nd quarter. Private Advisor Group LLC now owns 5,058 shares of the biopharmaceutical company’s stock valued at $5,317,000 after buying an additional 354 shares in the last quarter. Finally, New York Life Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. New York Life Investment Management LLC now owns 14,656 shares of the biopharmaceutical company’s stock valued at $15,404,000 after buying an additional 132 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.